Australia's largest stock trading and investment forum Australia's #1 stock forum

RAP

Click for more information

0.00%

20.5¢ resapp health limited

Ann: Continued Use of ResAppDx at COVID-19 Respiratory Clinic, page-182

First 182 Last

Share
Profile

Follow
Red bar

2,574 Posts.

4962

07/01/21

13:44

Post #: 50007728
Share

Originally posted by eason2946 ↑

Hi all,

It's been a while since I posted on RAP thread. I find it less and less motivational for me to post here because 2020 has been absolutely brutal for RAP. Started off at 31c and closed at 8.5c, a loss of 74%. There's no denying in that - these are the facts.

There were definitely positives in 2020 such as integration with Australian telehealth partners Coviu & Phenix, SleepCheck launched internationally, adoption of ResAppDx COVID-19 respiratory clinic...etc.

But one thing TK and its BOD has failed to demonstrate over and over again is: how is ResApp going to successfully commercialise its technologies to become a profitable company? Yes there are commercial deals in place and potentially more to come in the near future from Europe. But what exactly is the business model and how much is ResApp going to get from those deals? Since we're now in "revenue phase", how come SHs still don't know how much of the "$5-$10 per test" are we actually receiving. I'm also struggling to understand why is it so difficult for TK & Co to provide an estimate of revenue. Unless, even they don't know how much to expect which in that case, how can investors value the company?

For me, strike one was the poorly run initial US clinical trial. Strike two was the rejection of FDA application.

Now, termination of MOU with RB was the final strike and I've decided to completely sold out of RAP. I've invested in RAP for nearly 4 years and I believe I've given it enough patience.

IMO the technology works and it still has potential. But unfortunately, the leadership group has no idea how to take it to the next level, generate revenue and create wealth for shareholders, to put it bluntly. I believe the only way to turn things around is to put a CEO who's able to negotiate and sign material deals quickly and TK to step down as technical advisor or a director.

I guess I'm lucky that I've taken profit whenever I could and overall I'm very fortunate to have only lost a small amount of my investment. I truly hope RAP can revive in 2021 and when it does, I might consider buy it back. But until TK do something about it, unfortunately it could mean more of the same and more CR in the future.

Also wanted to thank all the fellow SH who have contributed their time and effort to post it here and inform others. You know who you are. Others who who still blindly defend RAP & TK for every negative news that's been released and attack posters who don't agree with them, time for you to look in the mirror and face the reality.

It's hard for me to post this as I was one of the biggest believers & advocates for RAP. But that's in the pass and it's time to move on.

GLTAH and DYOR

Expand

Well said and sorry to see you go mate hopefully you will have a better year in picking out some winners on the ASX....
Currently I too am disappointed with managements performance from an investor standpoint. During 2020 ResApp did make quite a few internal achievements but these achievements didn't help ratify the share price drifting further. strongly believe in the technology but the team delivering it need to improve otherwise we are going to have to act accordingly... TK has a very calm cool and collective approach in running this company but he doesn't really seem at all concerned about the short-term his main focus is on longer-term... This mindset has led to the new 52-week low and disgruntled shareholders... We need further updates, partnerships and most importantly dollars

I'm liking that latest update to the DX which will allow for consumers to have a smooth and efficient quality service from their healthcare provider. The next step is to get reimbursement for DX and listed on health direct for stronger sales potential here in Australia...

I think the work ResApp are doing with Medgate is the biggest potential that I hold onto at the moment. Get this over the line and it's all systems go... I'm sure there are many other irons in the fire but the main thing that investors including myself want to see is revenue... restore confidence again management!! Deliver and this company will have a licence to print! When this day comes is anyone's guess but it's been a bloody long time coming... can't wait to see some light at the end of the tunnel...

Cheers

Red bar

RAP Price at posting: 7.9¢ Sentiment: Buy Disclosure: Held
41 Upvote

2 Great analysis

Reply

Top Stories

Week 27 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

IMM

Immutep reports strong response rate from immunotherapies treating carcinomas

Bitcoin investors need to know the risks

NIM

Nimy to raise $1.21M to explore 'newsy' WA targets

ASX hits all time high out the gate on Friday trades following bullish US inflation data

AII

Almonty locks in govt agreement for tungsten oxide plant in South Korea

SKS

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

BHP

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

MDI

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

I88

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

There are more pages in this discussion • 51 more messages in this thread...

First 182 Last

Add RAP (ASX) to my watchlist